MBL or CLL: Which Classification Best Categorizes the Clinical Course of Patients with an Absolute Lymphocyte Count ≥5 × 10(9)/L but a B-cell Lymphocyte Count <5 × 10(9)/L?

Por Shanafelt, Tait D., Kay, Neil E., Call, Tim G., Zent, Clive S., Jelinek, Diane F., LaPlant, Betsy, Morice, William G., Hanson, Curtis A.
Publicado em 2008

Brief Report: Pre-treatment Angiogenic Cytokines Predict Response to Chemoimmunotherapy in Patients with CLL

Por Shanafelt, Tait D., Byrd, John C., LaPlant, Betsy, Zent, Clive S., Call, Tim, Secreto, Charla, Grever, Michael R., Lin, Thomas S., Kay, Neil E.
Publicado em 2009

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

Por Shanafelt, Tait D., Geyer, Susan M., Bone, Nancy D., Tschumper, Renee C., Witzig, Tom E., Nowakowski, Greg S., Zent, Clive S., Call, Tim G., LaPlant, Betsy, Dewald, Gordon W., Jelinek, Diane F., Kay, Neil E.
Publicado no Br J Haematol (2008)

Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia

Por Shanafelt, Tait D., Call, Tim G., Zent, Clive S., LaPlant, Betsy, Bowen, Deborah A., Roos, Michelle, Secreto, Charla R., Ghosh, Asish K., Kabat, Brian F., Lee, Mao-Jung, Yang, Chung S., Jelinek, Diane F., Erlichman, Charles, Kay, Neil E.
Publicado em 2009

Phase 2 Trial of Daily, Oral Polyphenon E in Patients with Asymptomatic, Rai Stage 0-II Chronic Lymphocytic Leukemia(CLL)

Por Shanafelt, Tait D., Call, Tim G., Zent, Clive S., Leis, Jose F., LaPlant, Betsy, Bowen, Deborah A., Roos, Michelle, Laumann, Kristina, Ghosh, Asish K., Lesnick, Connie, Lee, Mao-Jung, Yang, Chung S., Jelinek, Diane F., Erlichman, Charles, Kay, Neil E.
Publicado em 2012

Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy

Por Sinha, Sutapa, Boysen, Justin C., Chaffee, Kari G., Kabat, Brian F., Slager, Susan L., Parikh, Sameer A., Secreto, Charla R., Call, Tim, Shanafelt, Tait D., Leis, Jose F., Warner, Steven L., Bearss, David J., Ghosh, Asish K., Kay, Neil E.
Publicado no Oncotarget (2018)

Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study

Por Larsen, Jeremy T., Shanafelt, Tait D., Leis, Jose F., LaPlant, Betsy, Call, Tim, Pettinger, Adam, Hanson, Curtis, Erlichman, Charles, Habermann, Thomas Matthew, Reeder, Craig, Nikcevich, Daniel, Bowen, Deborah, Conte, Michael, Boysen, Justin, Secreto, Charla, Lesnick, Connie, Tschumper, Renee, Jelinek, Diane, Kay, Neil E., Ding, Wei
Publicado no Am J Hematol (2017)